HOOK - Hookipa CMV vaccine shows positive effect in mid-stage study

Hookipa (HOOK) announces positive interim data from a Phase 2 clinical trial evaluating cytomegalovirus ((CMV)) vaccine candidate HB-101 in patients receiving a transplanted kidney from a live donor.41 CMV-negative patients were evaluated for CMV-neutralizing antibody titers to HB-101. Eight received three doses of HB-101 pre-transplant, 19 received two doses and 14 received placebo. 48% of those who received three doses of HB-101 showed reduced CMV in the blood (viremia) and 42% needed less antiviral therapy. No CMV disease was observed in the treatment group compared to 14% (n=2/14) in the control group.Response to a two-dose schedule did not show an improvement compared to placebo, which is consistent with the low levels of CMV-neutralizing antibody in the two-dose group as well as with the T cell data reported in June 2020 for the two-dose group.Additionally, 33 CMV-negative patients were evaluated for CMV-neutralizing antibody titers to HB-101 on the day of transplantation, a subset of the 41 included in the

For further details see:

Hookipa CMV vaccine shows positive effect in mid-stage study